Read More Pharma Industry News Alpha Tau advances alpha DaRT with FDA approval for recurrent prostate cancer study Find out how Alpha Tau’s FDA-approved prostate cancer trial could redefine localized salvage therapy and reshape treatment for recurrent disease. bySoujanya RaviDecember 2, 2025